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ABSTRACT: Synthetic cannabinoids (SCs) continue to be the largest group of new psychoactive substances (NPS) monitored by 
the European Monitoring Center of Drugs and Drugs of Abuse (EMCDDA). The identification and subsequent prohibition of single 
SCs has driven clandestine chemists to produce analogues of increasing structural diversity, intended to evade legislation. That 
structural diversity, combined with the mostly unknown metabolic profiles of these new SCs, poses a big challenge for the 
conventional targeted analytical assays, as it is difficult to screen for ‘unknown’ compounds. Therefore, an alternative screening 
method, not directly based on the structure but on the activity of the SC, may offer a solution for this problem. We generated stable 
CB1 and CB2 receptor activation assays based on functional complementation of a split NanoLuc luciferase and used these to test 
an expanded set of recent SCs (UR-144, XLR-11 and their thermal degradation products; AB-CHMINACA and ADB-
CHMINACA) and their major phase I metabolites. By doing so, we demonstrate that several major metabolites of these SCs retain 
their activity at the cannabinoid receptors. These active metabolites may prolong the parent compound’s psychotropic and 
physiological effects and may contribute to the toxicity profile. Utility of the generated stable cell systems as a first-line screening 
tool for SCs in urine was also demonstrated using a relatively large set of authentic urine samples. Our data indicate that the stable 
CB reporter assays detect CB receptor activation by extracts of urine in which SCs (or their metabolites) are present at low- or 
subnanomolar (ng/ml) level. Hence, the developed assays do not only allow activity profiling of SCs and their metabolites, it may 
also serve as a screening tool, complementing targeted and untargeted analytical assays and/or preceding analytical (mass 
spectrometry based) confirmation. 
Synthetic cannabinoids (SCs) continue to be the largest 
group of new psychoactive substances (NPS) monitored by the 
European Monitoring Center of Drugs and Drugs of Abuse 
(EMCDDA).
1
 These “legal” alternatives for cannabis were 
first reported in 2008, at the time containing JWH-018 and CP 
47,497-C8.
2-3
 Many novel SCs were discovered since then, 
acting as agonists at the cannabinoid receptor 1 (CB1) and 2 
(CB2). Although various products are labeled with warnings 
like ’not for human consumption‘, they are intended to mimic 
the psychoactive effects of cannabis. Many SCs are unknown 
prior to first detection by forensic chemists, and little to 
nothing is known about their activity in humans. The lack of 
data regarding the pharmacological and toxicological 
properties of emerging SCs poses worldwide a continuous 
challenge for scientists, healthcare workers, and lawmakers.
4-6
 
The identification and subsequent prohibition of single SCs 
has driven clandestine chemists to produce analogues of 
increasing structural diversity, intended to evade legislation.
5, 
7-8
 Legislations based on individual structures are consequently 
stepping behind, but also the newer analogue laws in the US 
(2012)
9
 and UK (2016)
10
 controlling all “cannabimimetic” 
agents and substances with psychoactive properties (e.g. via 
the CB1 receptor) are challenged as the specific pharmacology 
of these new compounds is widely unknown.
11
 This could be 
efficiently countered by applying these new compounds in 
biological assays to establish their cannabinoid activity and 
therefore their illegality. The structural diversity, combined 
with the mostly unknown metabolic profiles of these new SCs,  
also poses a big challenge for the conventional targeted 
analytical assays, as it is difficult to screen for ‘unknown’ 
compounds.
5, 7, 12
 Although untargeted methods (e.g. high 
resolution mass spectrometry) are capable to screen for 
‘unknown’ substances, these methods have limitations 
capacity- and sensitivity-wise. Immunoassays based on 
specific antibodies are of limited use because of missing cross-
reactivity and insufficient sensitivity.
13
 Therefore, alternative 
screening methods not directly based on the structure of the 
SC may offer a solution for this problem. An activity-based 
assay may serve this purpose, by functioning as a first-line 
screening tool, complementing the conventional targeted and 
untargeted analytical methods. However, the detection of low 
concentrations of SCs in biological fluids requires high 
sensitivity bioassays, capable of monitoring low- or 
subnanomolar (ng/ml) concentrations of SCs. Also, the 
presence of active metabolites is a prerequisite if the screening 
tool is to be applied on urine samples, as SCs are extensively 
metabolized.
14
 The presence of active metabolites was 
demonstrated following metabolism of JWH-018, JWH-073, 
XLR-11, JWH-122, MAM-2201, JWH-210, EAM-2201, PB-
22 and 5F-PB-22.
15-20 
We recently reported on novel cell based 
CB reporter bioassays for the activity-based detection of SCs 
and their metabolites, demonstrating cannabinoid activity in an 
authentic urine sample as a proof-of-concept.
18
 The principle 
of this cell based bioassays is activity-based, where activation 
of the CB1 or CB2 receptor leads to β-arrestin 2 (βarr2) 
recruitment, which results in functional complementation of a 
split NanoLuc luciferase. This functional complementation 
restores the NanoLuc luciferase activity, resulting in a 
bioluminescent signal in the presence of the substrate 
furimazine, which can be read out with a standard 
luminometer. While the proof-of-concept of our CB reporter 
bioassays was successful, there were several limitations. First, 
the transient transfection used imposed a heavy workload and 
suffered from significant inter-experiment variability 
(depending on the transfection efficiency). Second, only a 
limited set of SCs (and metabolites) were tested. Third, only a 
proof-of-concept for one single user was demonstrated. To 
overcome these limitations, we generated stable cell systems 
and applied these on an expanded set of more recent SCs (UR-
144, XLR-11 and their thermal degradation products; AB-
CHMINACA and ADB-CHMINACA) and their major phase I 
metabolites. 
UR-144 and its 5-fluoro analogue, XLR-11, belong to the 
tetramethylcyclopropyl indolyl ketone family (see Figure 1A 
and 1B). They were first reported to the EMCDDA in 
February 2012 by Latvian (XLR-11), Finnish and Polish (UR-
144) authorities. The use of UR-144 and XLR-11 has been 
associated with acute kidney injury, acute ischemic events 
(upon inhalation) and death.
21-24
 AB-CHMINACA and ADB-
CHMINACA are part of a particularly prevalent class of SCs, 
first described in a Pfizer patent.
25
 Their structure is comprised 
of an indazole core, modified by a cyclohexylmethyl group at 
the 1-position, and a valine- or tert-leucine-derived 
carboxamide moiety at the 3-position (see Figure 1C and 1D). 
AB-CHMINACA was formally reported to the EMCDDA in 
April 2014 following identification in Latvia,
26
 and was later 
detected in various countries all over the world.
27-28
 ADB-
CHMINACA was first reported in September 2014 in 
Hungary.
26
 The use of AB-CHMINACA and ADB-
CHMINACA was implicated in clinical reports of acute 
delirium, agitation, seizures, respiratory failure and death.
24, 29-
32
 For most of the metabolites of these SCs, there is no 
information on their cannabinoid receptor activities. As it was 
demonstrated that several SCs are metabolized to a number of 
highly active metabolites,
15-20
 activity-profiling of UR-144, 
XLR-11, their thermal degradation products, AB-
CHMINACA and ADB-CHMINACA and their major phase I 
metabolites might help to explain the distinct adverse clinical 
manifestations that were observed with the use of these drugs. 
Finally, the generated stable cell systems were applied on a 
relatively large set of authentic urine samples to evaluate their 
potential as a screening tool for SCs in urine. 
MATERIALS AND METHODS 
Chemical Reagents. 
All chemical reagents used are listed in Supporting 
Information Data S-1. Blank urine samples were donated by 
volunteers and tested for the absence of SCs and their 
metabolites prior to use. Mobile phase A (1% acetonitrile, 
0.1% formic acid and 2mM ammonium formate in water) and 
mobile phase B (0.1% formic acid, 2 mM ammonium formate 
in acetonitrile) were freshly prepared prior to LC-MS/MS 
analysis. 
Retroviral Constructs. 
The CB1−LgBiT, CB2−SmBiT, SmBiT−βarr2 and 
LgBiT−βarr2 expression vectors were generated as previously 
described.
18
 To generate the retroviral vectors, the coding 
sequences of interest, flanked by BamHI/EcoRI (for 
CB1−LgBiT and CB2−SmBiT) or BamHI/NotI restriction 
sites (SmBiT−βarr2 and LgBiT−βarr2) were PCR-amplified 
and cloned into corresponding digested retroviral vectors 
pLZRS-IRES-EGFP (CB-constructs) or pLZRS-IRES-dNGFR 
(βarr2-constructs), as described in Supporting Information 
Data S-2. The integrity of all retroviral plasmids was 
confirmed by DNA sequencing. This yielded four retroviral 
vectors, each of which leads to co-expression of a gene of 
interest with either Enhanced Green Fluorescent Protein 
(EGFP) for the CB-constructs or truncated Nerve Growth 
Factor Receptor (dNGFR) for the βarr2-constructs. These 
markers (EGFP and dNGFR) can be used for cell sorting and 
to check the stability of the cell lines by flow cytometry.  
Production of Retrovirus and Retroviral Transduction. 
The Phoenix-Amphotropic packaging cell line
33
 (a kind gift 
from prof. Bruno Verhasselt, Department of Clinical 
Chemistry, Microbiology, and Immunology, Ghent University, 
Belgium) was transfected with the LZRS-(CB-insert)-IRES-
EGFP and the LZRS-(βarr2-insert)-IRES-dNGFR plasmids, 
by using calcium phosphate precipitation (Invitrogen, San 
Diego, CA, USA). After two weeks of puromycin selection, 
the retroviral supernatant was harvested, spun (10 min at 350 
× g) and aliquots of the supernatant were stored at -80°C until 
use. For transduction of human embryonic kidney (HEK) 
293T, cells were seeded in a 96-well plate at 10
4
 cells/well. 
After 24 h, the medium was changed for the retroviral 
supernatant, which had been preincubated for 10 minutes with 
Dotap (Roche Diagnostics). The cells were co-transduced with 
viruses containing both CB and βarr2 constructs by mixing the 
respective retrovirus containing supernatants. To increase 
transduction efficiency, cells were spun (90 minutes, 950 × g, 
32°C). Transduction efficiency was evaluated by flow 
cytometry 48 hours after transduction, via assessment of 
expression of EGFP (for CB1-LgBiT and CB2-SmBiT) and 
dNGFR (for SmBiT-βarr2 and LgBiT-βarr2). For the latter, an 
APC-linked antibody against dNGFR was used 
(Chromaprobe, Inc.).  
Cell Sorting and Cell Culture. 
Cell sorting was done on a BD FACSAria III, equipped with 
405 nm, 488 nm, 561 nm, and 640 nm lasers (BD Biosciences, 
Erembodegem, Belgium). The cells needed to be positive for 
both EGFP and dNGFR, as they need to contain either the 
combination CB1−LgBiT/SmBiT−βarr2 or CB2−SmBiT/ 
LgBiT−βarr2. All cells were routinely maintained at 37°C, 5% 
CO2, under humidified atmosphere in DMEM (high glucose) 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), 2 mM of glutamine, 100 IU/ml of penicillin, 100 μg/ml 
of streptomycin and 0.25 μg/ml of amphotericin B. Stability of 
the cell lines was followed up by flow cytometric analysis. For 
experiments, cells were plated on poly-D-lysine coated 96-
well plates at 5x10
4
 cells/well and incubated overnight. 
Cannabinoid Reporter Assay.  
The cells were washed twice with Opti-MEM® I Reduced 
Serum Medium to remove any remaining FBS, and 100 μL of 
Opti-MEM® I was added. The Nano-Glo Live Cell reagent 
(Promega), a nonlytic detection reagent containing the cell 
permeable furimazine substrate, was prepared by diluting the 
Nano-Glo Live Cell substrate 20× using Nano-Glo LCS 
Dilution buffer, and 25 μl was added to each well. 
Subsequently, the plate was placed in a luminometer, the 
GloMAX96 (Promega). Luminescence was monitored during 
the equilibration period until the signal stabilized (30−45 min). 
For agonist experiments, we added 10 μl per well of test 
compounds, present as 13.5× stocks in 50% methanol in Opti-
MEM I. The luminescence was continuously detected for 120 
min. Solvent controls were run in all experiments; the final 
concentration of methanol (3.7%) did not pose a problem 
given the short readout time of the assay. 
  
Figure 1. Structures of SCs and metabolites. SCs belonging to the tetramethylcyclopropyl indolyl ketone family: UR-144 and XLR-11 (A) 
and thermal degradant products (B). AB-CHMINACA (C) and ADB-CHMINACA (D), which contain an indazole core modified at the 1-
position with a cyclohexylmethyl group, and at the 3-position with a valine- or tert-leucine-derived carboxamide. 
 Statistical Analysis.  
Curve fitting and statistical analyses were performed using 
GraphPad Prism software (San Diego, CA, USA). The results 
are represented as mean area under the curve (AUC) ± 
standard error of mean (SEM) with at least three replicates for 
each data point (unless stated otherwise). Curve fitting of 
concentration−effect curves via nonlinear regression was 
employed to determine EC50 (a measure of potency). To 
evaluate the activity of the different SCs and their metabolites, 
results are represented as the percentage (%) CB activation 
(relative to the maximum receptor activation of JWH-018) ± 
SEM, with at least three replicates for each data point. Here, 
the absolute signals were baseline-corrected by subtracting the 
vehicle control samples and were corrected for the inter-well 
variability before the AUC calculations (see Supporting 
Information Data S-3). A one-way ANOVA, followed by 
Dunnett’s post hoc test, was used to determine statistical 
significance (P < 0.05) (i) between all compounds and the 
reference compound JWH-018, (ii) within a group between a 
parent compound and the other compounds in that group (e.g., 
all compounds related to AB-CHMINACA vs. AB-
CHMINACA itself), and (iii) between the signals obtained 
from the compounds and those from solvent controls.  
Urine Sample Preparation.  
Conjugate cleavage was conducted by adding 0.5 ml 
phosphate buffer (pH 6) and 30 μl β-glucuronidase to 0.5 ml 
of urine, followed by 1 h incubation at 45 °C. Afterwards, 1.5 
ml ice-cold acetonitrile and 0.5 ml 10 M ammonium formate 
were added. The mixture was shaken and centrifuged. One 
milliliter of the organic phase was transferred to a separate vial 
and evaporated to dryness under a stream of nitrogen at 40 °C. 
For analysis with the CB reporter assays, the evaporated 
extract was reconstituted in 100 μl of Opti-MEM I/MeOH 
(50/50, v/v), of which 10 μl was used per well (see the 
Cannabinoid Reporter Assay section). For LC-MS/MS 
analysis, another 0.5 ml aliquot was spiked with reference 
standards and internal standards (IS), if applicable, and 
processed as described above. The residue was reconstituted in 
200 μl of mobile phase A/B (50/50, v/v) prior to LC-MS/MS 
analysis. Fortified calibration samples (0.05, 0.1, 0.25, 0.5, 
1.0, 2.5, 5.0, 10.0, 25.0, 50.0 ng/ml), control samples (0.07, 
0.4, 4.0, 20.0, 40.0 ng/ml), as well as blank and zero (blank 
with IS) samples were used for quantification and method 
validation. The concentration of IS in the samples was 0.4 
ng/ml for all IS, except for JWH-200-D5 (0.8 ng/ml). 
LC-ESI-MS/MS Analysis of Urine Samples.  
Quantification of SCs and their metabolites in authentic urine 
samples was performed by applying a fully validated LC-ESI-
MS/MS method operating in positive MRM mode. Technical 
details concerning chromatographic and ionization conditions 
were reported elsewhere
34
, while the optimized MS parameters 
for each compound are listed in Supporting Information Data 
S-4. The method validation was conducted in accordance to 
the guidelines of the German speaking Society of 
Toxicological and Forensic Chemistry (GTFCh).
35
 All 
validation data are summarized in Supporting Information 
Data S-5. In brief: selectivity was tested by analyzing different 
blank urine samples and no relevant interferences were 
observed. Linearity was achieved between 0.01 and 50.0 
ng/ml, depending on the analyte. Calibration curves of UR-
144 and XLR-11 as well as their degradation products and 
metabolites showed relatively steep slopes leading to rapid 
saturation of the detector and relatively narrow dynamic 
ranges. Since concentrations of the pentanoic acid metabolites 
of UR-144 and its degradation product are usually relatively 
high in authentic urine samples, additional quantification via 
quadratic regression was validated to extend the dynamic 
range for these two compounds. Limits of detection (LODs) 
ranged from 0.01 to 0.25 ng/ml. Limits of quantification 
(LOQs) ranged from 0.05 to 0.25 ng/ml. Accuracy of the 
method showed a bias between -9.4% and 13.1%, inter-day 
precision was below 11%, and intra-day precision below 10% 
over the analyzed control levels (0.07, 0.4, 4.0, 20.0, 40.0 
ng/ml). Matrix effects and recoveries were evaluated 
according to the procedure suggested by Matuszewski et al.
36
 
While matrix effects were between 87 and 151% and showed 
standard deviations below 18% for most compounds and 
concentration levels, matrix effects were more pronounced at 
the lowest control level (0.07 ng/ml) and for ADB-
CHMINACA M1 with a maximum enhancement of 213% and 
maximum standard deviation of 45%. In general, recoveries 
were between 81 and 94%, with small standard deviations 
(below 8%) for most compounds and concentration levels. 
Significantly lower recoveries were observed at the lowest 
concentration level (0.07 ng/ml) and for the compounds AB-
CHMINACA M3A and ADB-CHMINACA M3 (the most 
polar substances covered by the method), with extreme values 
of 27%, but still sufficient reproducibility (standard deviations 
below 7%).  
RESULTS AND DISCUSSION 
Stable expression of the Cannabinoid Reporter Assay.  
The cannabinoid reporter assays utilize a structural 
complementation-based approach to monitor protein 
interactions within living cells (NanoLuc Binary Technology). 
It makes use of inactive subunits of NanoLuc luciferase, Large 
BiT (LgBiT; 18 kDa) and Small BiT (SmBiT; 1 kDa), which 
are coupled to two proteins of interest, which are in our case 
the cannabinoid receptors, CB1 and CB2, and β-arrestin 2 
(βarr2). Upon CB activation, the cytosolic βarr2 protein 
interacts with the receptor, leading to receptor desensitization 
and internalization. That interaction promotes structural 
complementation of the NanoLuc luciferase subunits, thereby 
restoring luciferase activity, which generates a bioluminescent 
signal in the presence of the furimazine substrate. 
 
Figure 2: Setup of the CB reporter assays for CB1 and CB2: 
CB1−LgBiT/SmBiT−βarr2 and CB2−SmBiT/LgBiT−βarr2. 
We previously set up and applied this reporter system in a 
transient format in which cells were transiently transfected, 
demonstrating applicability using a limited panel of SCs and 
providing a proof-of-principle for one authentic urine 
sample.
18
 Here, we report on the establishment of two stable 
cell lines, either expressing the fusion proteins 
CB1−LgBiT/SmBiT−βarr2 or CB2−SmBiT/LgBiT−βarr2 (see 
Figure 2). These cell lines were obtained following retroviral 
transduction of HEK293T cells and flow cytometry-assisted 
cell sorting, to yield cell lines co-expressing the CB1 or CB2 
construct with a βarr2 construct, with a purity of ≥ 93%. Via 
flow cytometric analysis of the co-expressed markers EGFP 
and dNGFR, the stability of these cell lines can be monitored 
in time (see Supporting Information Data S-6). This is 
important, since expression of these constructs may impose a 
negative effect on growth, which would jeopardize the cell 
line’s utility in long term. We indeed observed some decrease 
in double positive (EGFP+ and dNGFR+) cells in time and 
utilized the cells until passage 20, in which double positivity 
remained ≥ 70%. Up to this point, we did not notice a 
measurable effect on our systems’ performance. Yet, if 
deemed necessary, the stably co-expressed markers always 
offer the possibility to submit the cell lines to another round of 
cell sorting.  
Upon stimulation of the stable systems with a known 
agonist, JWH-018, CB1−LgBiT and CB2−SmBiT showed a 
concentration-dependent interaction with SmBiT−βarr2 and 
LgBiT−βarr2, respectively, with EC50 values of 23.9 nM (95% 
CI: 18.3-31.6) and 6.8 nM (95% CI: 3.3-13.8). These values 
are in good correspondence with those determined using the 
transient system (CB1: 38.2 nM (95% CI: 27.1−55.7), CB2: 
12.8 nM (95% CI: 5.6−26.0)).
15
 The stable system was also 
applied on UR-144, XLR-11, AB-CHMINACA, and ADB-
CHMINACA. Concentration-dependent curves were obtained 
and EC50 values were determined as a measure of relative 
potency (Figure 3 and Table 1).  
 
 
Figure 3. The concentration-dependent interaction of CB1 (A) 
and CB2 (B) with βarr2 upon stimulation with different SCs. 
AUC, area under the curve. Data are given as mean AUC ± 
SEM (n=5-6). 
Drug CB1 EC50 (nM) CB2 EC50 (nM) 
JWH-018 23.9 (18.3-31.6) 6.8 (3.29-13.8) 
UR-144 426 (312-635) 7.4 (4.5-12) 
XLR-11 179 (113-285) 2.8 (1.0-6.6) 
AB-CHMINACA 6.1 (3.1-11.4) 3.7 (2.1-6.3) 
ADB-CHMINACA 1.49 (0.69-2.61) 2.2 (1.0-4.3) 
Table 1. EC50 values of different SCs. EC50 values are 
presented as a measure of potency. Data are given as EC50 
values (95% CI profile likelihood). 
Although it is difficult to compare EC50 values from 
different assays (due to different experimental setups), our 
values are in line with those found in the literature. E.g. it is 
known that UR-144 and XLR-11 bind CB2 with a higher 
affinity than CB1.
37-39
 This is not surprising, given that these 
compounds are structurally related to a series of indol-3-yl-
cycloalkyl ketones that were originally synthesized by Abbott 
Laboratories as part of their effort to develop CB2-selective 
cannabinoids.
37
 That CB2 selectivity is reflected in our in vitro 
functional data. Banister et al. also reported a clear CB2 
preference for UR-144 (FLIPR membrane potential assay in 
AtT-20 cells), although for XLR-11 an equal level of 
activation of both CB receptors was found.
12
 This may derive 
from the fact that the studies were done on different cell types, 
which may lead to different signaling pathways. Our in vitro 
functional data also confirm that AB-CHMINACA and ADB-
CHMINACA are highly potent SCs, which is consistent with 
the low EC50 values reported in literature, varying from 0.278-
7.8 nM and 21 nM (for AB-CHMINACA), for respectively 
CB1 and CB2.
12,
 
25, 40-41
 Interestingly, our finding that ADB-
CHMINACA is about 4 times more potent than AB-
CHMINACA at CB1 confirms data from an earlier report by 
Buchler et al. (GTPγS binding assay in CHO cell membranes, 
EC50 values for CB1 of 2.55 nM and 0.620 nM for AB-
CHMINACA and ADB-CHMINACA, respectively).
22
 For the 
efficacy in terms of βarr2 recruitment, we observed that both 
AB-CHMINACA and ADB-CHMINACA showed a stronger 
βarr2 recruitment at CB1 than JWH-018, a known full agonist 
at CB1, an observation we also made for other SCs, such as 
JWH-122, JWH-210, PB-22 and their 5-fluoro-analogues.
18
 
Application of the CB Reporter Assays on SCs and Their 
Main Phase I Metabolites.  
UR-144 and XLR-11 
Biotransformation of UR-144 and XLR-11 (and their 
thermal degradant products, generated by smoking)
38, 42-43
 
leads to common phase I metabolites: the N-pentanoic acid 
UR-144 and N-pentanoic acid UR-144 degradant metabolites. 
UR-144 metabolism also results in trace amounts of the 4-OH-
pentyl-UR-144 metabolite, whereas for XLR-11, the 5-OH-
pentyl-UR-144 and 4-OH-pentyl-XLR-11 metabolites are also 
found in authentic urine samples (unpublished observations).
44
 
The ring open degradants of XLR-11 and UR-144 were 
reported to possess a higher affinity than their parent 
compounds at both CB receptors.
35
 Also for the 5-OH-pentyl-
UR-144 metabolite, there is already some information on the 
binding and the functional activity (via FLIPR membrane 
potential assay) at the CB receptors. More specifically, it was 
reported to be CB2 selective.
15, 37
 Since, apart from the above-
described limited and fragmented information, the activity of 
most UR-144 and XLR-11 metabolites at CB receptors is not 
known, we evaluated these with our CB reporter bioassays. 
For each of these compounds, we assessed CB1 and CB2 
receptor activation, at a receptor saturating concentration (10 
μM), with JWH-018 as a reference (Figure 4, Supporting 
Information Data S-7). 
UR-144, XLR-11, their degradant products, and their 
metabolites all showed significant CB1 receptor activation, 
although there were major differences between the different 
compounds (see Figure 4). UR-144, 4-OH-pentyl-UR-144, 5-
OH-pentyl-UR-144, 4-OH-pentyl-XLR-144, and both N-
pentanoic acid metabolites show a significantly lower level of 
CB1 activation relative to the reference JWH-018, whereas the 
degradant product of UR-144 shows a significantly higher 
level of receptor activation. XLR-11 and its degradant show a 
similar level of activation compared to JWH-018. For both 
degradants it was reported that they show an increase in Emax 
at CB1 compared to UR-144 and XLR-11 (GTPγS binding 
assay in HEK293 cell membranes)
38
, although we only 
observed this for the UR-144 degradant. At CB2, UR-144, its 
degradant product, and its metabolites all showed significant 
receptor activation, which was not significantly different from 
the reference compound JWH-018. Only UR-144 degradant 
pentanoic acid showed a slightly lower level of activation 
compared to its parent compound UR-144. For XLR-11, both 
the XLR-11 degradant product and the 4-OH-pentyl 
metabolite showed a lower level of CB2 activation relative to 
XLR-11, but they did not significantly differ from the 
reference JWH-018. Our findings are consistent with those 
reported in literature, in which a similar Emax at CB2 for UR-
144 and XLR-11 was reported, although we observed a 
statistically significant difference when comparing the XLR-
11 degradant with XLR-11.
38 
This difference could be related 
to the different experimental setup. 
AB-CHMINACA and ADB-CHMINACA.  
To select the major phase I metabolites of AB-CHMINACA 
and ADB-CHMINACA that were to be tested in our CB 
reporter bioassays, we first analyzed authentic urine samples 
via LC-ESI-MS/MS to identify these. For AB-CHMINACA, 
the major phase I metabolites identified are the 4-OH-AB-
CHMINACA (M1A), valine-AB-CHMINACA (M2), 4-OH-
valine-AB-CHMINACA (M3A), and two isomers of the M3A 
metabolite. The latter two could not be tested for activity as no 
reference standards were available. The 3-OH-AB-
CHMINACA metabolite (M1B) was present to a lesser extent 
(unpublished observations). In previous studies on 
identification and quantification of metabolites of AB-
CHMINACA in urine specimens from abusers, metabolites 
monohydroxylated on the cyclohexyl moiety (corresponding 
to M1A and M1B) and another metabolite carboxylated at the 
terminus of the amide linker (M2) were detected.
32, 45-48
 Also 
the combination of both metabolites (monohydroxylation at 
cyclohexyl moiety and carboxylation at the outer amide) were 
reported to be found in urine specimens (M3A and isomers).
31, 
45
 For ADB-CHMINACA, major metabolites in the authentic 
urine samples were 4-OH-ADB-CHMINACA (M1), an M1 
isomer, 4-OH-valine-ADB-CHMINACA (M3), and four M3 
isomer metabolites. Also the valine-ADB-CHMINACA (M2) 
metabolite was found in authentic urine samples (unpublished 
observations). The M1 and M3 metabolite isomers of ADB-
CHMINACA were not available as reference standards and 
could therefore not be tested. Using human hepatocyte 
cultures, Carlier et al. also recently found M1 and its isomer to 
be important ADB-CHMINACA metabolites. These authors 
did not identify any carboxylated metabolites (M2 and M3), 
which may be owing to the limitation of using in vitro systems 
for mimicking human metabolization.
47 
Very recently, 
Hasegawa et al. reported on the identification and 
quantification of 2 predominant metabolites of ADB-
CHMINACA in an authentic post-mortem human urine 
specimen: the M1 metabolite and the M11 metabolite 
(corresponding to the M1 metabolite, with additional 
hydroxylation at the tert-butyl moiety in the amide linker).
48 
The latter was only reported to be a minor metabolite by 
Carlier et al. and was not present in the authentic urine 
samples we examined from different living individuals. 
Hence, we did not include M11 as a test compound in our 
assay.
47 
For both AB- and ADB-CHMINACA also the parent 
compound was present in urine samples containing high 
concentrations of metabolites (unpublished observations). 
Each of these compounds was evaluated with our bioassays at 
a receptor saturating concentration (10 μM), with JWH-018 as 
a reference (Figure 4, Supporting Information Data S-7). 
AB-CHMINACA, ADB-CHMINACA, and all evaluated 
metabolites, except 4-OH-valine-AB-CHMINACA (M3A), 
showed significant CB1 and CB2 activation, although there 
were major differences between the different compounds. The 
highest signals were obtained for the parent compounds, AB-
CHMINACA and ADB-CHMINACA, which showed a 
significantly higher level of CB1 activation relative to JWH-
018. While, as compared to the parent compounds, all 
metabolites showed a reduced level of CB1 activation, the 
valine-AB-CHMINACA metabolite (M2) still displayed a 
significantly stronger level of CB1 activation than JWH-018. 
For 4-OH-AB-CHMINACA (M1A) and 3-OH-AB-
CHMINACA (M1B), as well as for the monohydroxylated 
metabolite of ADB-CHMINACA (M1), there was no 
significant difference compared to the reference JWH-018. 4-
OH-valine-AB-CHMINACA (M3A) showed the lowest level 
of CB1 activation. Also CB1 activation by valine-ADB-
CHMINACA (M2) and 4-OH-valine-ADB-CHMINACA 
(M3) was significantly lower than that induced by JWH-018. 
At CB2, all compounds, except 4-OH-valine-AB-
CHMINACA (M3A), yielded a signal that was not 
significantly different from that of the reference JWH-018. 
The finding that the valine metabolites of AB-CHMINACA 
and ADB-CHMINACA (M2 metabolites) still showed CB1 
activation was surprising, because these metabolites were 
reported to have little, if any, affinity to the CB1 receptor (Ki 
= 380 nM and Ki > 4010 nM, respectively).
25
 Overall, these 
data demonstrate that, although metabolization results in a 
reduced activity in all instances, the vast majority of 
metabolites still has considerable activity at CB1 and CB2 (in 
many cases comparable with the reference JWH-018). Only 
when the valine metabolite is additionally hydroxylated (or, 
vice versa, when in the hydroxylated metabolite the outer 
amide group is oxidized to a carbonyl group), most activity is 
lost. 
 
Figure 4. Activation of CB1 receptor (A) and CB2 receptor 
(B). Values designated with (a) above error bars denote a 
significant difference from the reference compound, JWH-018 
(P ≤ 0.05, one-way ANOVA with Dunnett’s multiple 
comparison post hoc test). Values designated with (b) are 
significantly different from the reference compound within a 
group (groups are separated via vertical dotted lines). Bars 
assigned with an (*) are not significantly different from basal 
levels. Data are given as the mean percentage CB receptor 
activation (in comparison to the receptor activation of the 
reference, JWH-018) ± SEM (n = 4). 
Application of the CB Reporter Assays on authentic urine 
samples from SC users. 
Two batches of urine samples were analyzed. Samples of the 
first batch mainly comprised urine samples positive for 
metabolites of UR-144, XLR-11, AB-CHMINACA, or ADB-
CHMINACA as confirmed via LC-ESI-MS/MS analysis. 
Analysis of this batch served to evaluate the sensitivity of the 
bioassays. The second batch of authentic urine samples 
included a higher proportion of SC negative samples and was 
used to score the specificity. Both CB reporter assays were 
used to score urinary extracts from both batches. The scoring 
(positive/negative) of randomized samples was done blind-
coded by two individuals independently, who were unaware of 
the number of positives per batch. If the final scoring of the 
sample differed between the two individuals, which was 
eventually only the case for one sample, we conservatively 
decided to consider the sample negative.  
The first batch contained 42 urine samples (41 positives and 
1 negative) and was analyzed along with 4 known blanks (see 
Table 2). From the 18 urine samples from users who had 
consumed either UR-144 or XLR-11, 17 were scored positive 
(94.4%) (Table 2A). The extract of the one sample that was 
missed, was strongly colored and contained low levels of 
XLR-11 metabolites (see Table 2A). In general, a pronounced 
coloration of the extract was found to influence the signal 
obtained in the CB reporter assays (more specifically resulting 
in a drop of signal), which makes the scoring of such samples 
difficult (see Supporting Information Data S-8). The 
pronounced coloration is not linked to the creatinine content of 
the urine sample, as can be seen in Table 2. From the 12 
samples positive for AB-CHMINACA metabolites, only 4 
were scored positive (33.3%) (Table 2B). This low detection 
rate was unexpected, as the activity profiling of the AB-
CHMINACA metabolites (performed at 10 µM) had revealed 
activity at both CB1 and CB2. Further evaluation of the 
activity of the AB-CHMINACA metabolites demonstrated that 
the M1 metabolites had strongly reduced potency (see Figure 
5, right shift of the curves). This was less the case for the M2 
metabolite, although also here, the curve only started to rise at 
higher concentrations, compared to the JWH-018 reference 
(Figure 5). For the two negatively scored samples with M2 
metabolite > 50 ng/ml coloration of the extract may explain 
the false negative result. The false negative results of the other 
samples can likely be explained by the fact that the 
concentrations of the metabolites were too low to give rise to a 
signal that could clearly be distinguished from background. As 
some samples with relatively low metabolite concentrations 
were scored positive (though weakly), the metabolite 
concentrations in these samples might lie at the current assays 
tipping point.  
 
Figure 5. The concentration-dependent interaction of CB1 
with βarr2 upon stimulation with the major phase I metabo-
lites of AB-CHMINACA. AUC, area under the curve. Data 
are given as mean AUC ± SEM (n = 4-6). 
Nine out of 11 (81.8%) urine samples from users who had 
consumed ADB-CHMINACA were scored positive (Table 
2C). The two missed cases both contained lower 
concentrations of ADB-CHMINACA metabolites (approx. 2.5 
ng/mL of the major metabolite M1), one also being strongly 
colored, resulting in a drop of signal (see Supporting 
Information Data S-8). The unknown blank was scored 
correctly negative (not shown in Table 2). Overall, this leads 
to a sensitivity of 73.2% (30/41) for the first batch of urine 
samples. 
 
 
 
*level is determined by most potent metabolite (bold): + <1 ng/ml, ++ 1-10 
ng/ml, +++ 10-50 ng/ml, ++++ > 50 ng/ml. 
Table 2. List of authentic urine samples from users of UR-
144/XLR-11 (A), AB-CHMINACA (B), or ADB-CHMINACA 
(C). The intensity of the color of the extract is shown by the 
different shades of gray. 
The second batch contained 32 urine samples (8 SC positive 
and 24 SC negative samples) and was analyzed along with 4 
known blanks (Table 3). The SC negative samples were full 
blanks (n=14), authentic urine samples containing (metabolites 
of) drugs of abuse (cocaine, diverse stimulants, THC, and 
opiates) and also a urine sample spiked with 1 µg/ml THC-
COOH (Table 3B). From the 8 samples from users who 
consumed either UR-144, XLR-11, AB-CHMINACA, and 
ADB-CHMINACA, 6 were scored positive, leading to a 
sensitivity of 75% (6/8), which aligns with the overall 
sensitivity of the first batch of urine samples (73.2% - 30/41). 
The extracts of the two samples that were missed contained 
AB-CHMINACA or ADB-CHMINACA metabolites at 
relatively low (AB-CHMINACA) or very low (ADB-
CHMINACA) concentrations (Table 3A). The sensitivity 
results are linked to the type of SCs included in the batch of 
analyzed urine samples. Other SCs can give different 
sensitivity rates. From the 24 SC negative urine samples, 19 
were scored negative. Amongst the 5 positively scored SC 
negative samples, three authentic urine samples contained 
THC-COOH (levels of other cannabis-related substances 
unknown), demonstrating use of natural cannabinoids. 
Although we confirmed that THC-COOH does not possess 
any detectable cannabinoid activity
18
 (see also spiked THC-
COOH sample 15 in Table 3B and Supporting Information 
Data S-8), the presence of other cannabinoids, such as THC 
and 11-OH-THC, may result in a (genuine) positive result in 
natural cannabis users. This does not pose a problem as these 
positive samples are also easily picked up by conventional 
(natural) cannabinoid screening methods. For two out of the 5 
positively scored SC negative samples, no explanation could 
be found for the positive scoring.  
 
*level is determined by most potent metabolite (+ <1 ng/ml, ++ 1-10 ng/ml, 
+++ 10-50 ng/ml, ++++ > 50 ng/ml) 
 
*level is determined by most potent metabolite (bold): + <1 ng/ml, ++ 1-10 
ng/ml, +++ 10-50 ng/ml, ++++ > 50 ng/ml. 
Table 3. List of authentic urine samples from users of UR-
144/XLR-11, AB-CHMINACA, or ADB-CHMINACA (A) and 
the SC negative urine samples (B). The intensity of the color 
of the extract is shown by the different shades of gray. 
Also additional screening with the ToxTyper approach
49
 did 
not reveal any relevant compounds. Hence these samples 
should be considered as genuine false positives. Therefore, we 
can conclude that our CB reporter bioassays yielded a false 
positive result in 2/21 cases, resulting in a specificity of 
90.5%. Application on an even larger scale – which is beyond 
the scope of this study – is warranted to confirm these 
percentages. 
CONCLUSION 
We successfully developed stable CB1 and CB2 receptor 
activation assays based on the principle of functional 
complementation of a split NanoLuc luciferase. In contrast to 
the initially developed assays, which were in a transient 
format
18
, the newly developed assays are in a stable cell 
format, offering a reduced workload, a higher reproducibility 
within experiments, and a control on stability, via co-
expressed markers. The CB reporter assays were applied to 
determine the in vitro activity of a new set of SCs (UR-144, 
XLR-11 and their thermal degradation products; AB-
CHMINACA and ADB-CHMINACA) and their metabolites at 
CB1 and CB2 receptors, revealing for the first time that 
several of their major phase I metabolites retain activity at the 
CB receptors. The high potency of SCs, in combination with 
their metabolism to a number of highly active metabolites, 
might help to explain the distinct adverse clinical 
manifestations that were observed with the use of these SCs. 
Interestingly, AB-CHMINACA and ADB-CHMINACA were 
more efficacious at CB1, compared to the known full agonist 
JWH-018, but whether this relates to more toxicity is 
unknown.  
Finally, we evaluated the utility of the bioassays as a 
screening method for SCs on a relatively large set of authentic 
urine samples. Given the continuous modifications to the SCs’ 
structure to circumvent laws on controlled substances, 
conventional targeted analytical methods struggle as it is 
difficult to continuously update ‘in-house’ libraries and to 
screen for ‘unknown’ compounds. Another critical problem is 
that these high-potency drugs often result in very low drug 
concentrations. Here, we are the first to apply an activity-
based screening method for the detection of SCs in a panel of 
authentic urine samples, therefore circumventing the need to 
know the specific structure of the SC. Our data indicate that 
the stable CB reporter assays detect CB receptor activation by 
extracts of urine in which SCs (or their metabolites) are 
present at low- or subnanomolar (ng/ml) level. The presence 
of other drugs (of abuse), tested here, did not influence the CB 
reporter bioassays. The presence of natural cannabinoids may 
give rise to a positive result though, which is not surprising as 
we screen for CB activity. Confirmation of these cannabis 
positive samples can be done via conventional THC assays 
and, if positive, actually does not require further testing for 
SCs as the person readily is considered positive. Two genuine 
blanks (9.5%) were falsely scored positive. Evaluation on 
large sample numbers –which is beyond the scope of the 
current study – is needed to further substantiate this. 
Application of colored extracts in our bioassays yielded false 
negative results in several instances. Optimization of 
extraction could possibly solve this issue. On the other hand, 
the data obtained for AB-CHMINACA – with a rather low 
detection rate of positive samples – indicate that there is still 
room for improvement of the CB receptor activation assays 
(something we are actively pursuing). The low detection rate 
with AB-CHMINACA is in contrast with the good sensitivity 
we obtained for the ADB-CHMINACA positive samples 
(81.8%). This may be related to subtle differences in metabolic 
pathways between AB- and ADB-CHMINACA, despite the 
minor structural difference (i.e. the propyl and tert-butyl 
moiety for AB- and ADB-CHMINACA, respectively), as well 
as to a difference in potency of metabolites of ADB- vs AB-
CHMINACA.
48
 Notably, while the AB-CHMINACA 
metabolites appear to have a reduced potency, several of these 
metabolites demonstrated high efficacy at both CB receptors. 
Hence, not surprisingly, the application of our bioassays on 
urine specimens relies on the presence of sufficiently high 
concentrations of sufficiently potent metabolites. Anyway, it 
should be kept in mind that these CB1/CB2 bioassays are 
meant to serve as a screening tool, complementing existing 
assays, with as unique advantages the independence of mass-
based information, as well as the fact that no antibody 
recognition is required. Indeed, immunoassay-based SC 
screening strategies have been demonstrated to have limited 
value, recognizing only clearly related structures, which is not 
surprising.
13
 Therefore, we believe that our data do support the 
potential of deploying CB receptor activation assays as a ﬁrst-
line screening tool to detect SC use in urine samples, 
complementing targeted and untargeted analytical assays 
and/or preceding analytical (mass spectrometry based) 
conﬁrmation. 
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